Prediction of the human in vivo antiplatelet effect of S- and R-indobufen using population pharmacodynamic modeling and simulation based on in vitro platelet aggregation test

Indobufen (Ibustrin®), a reversible inhibitor of platelet aggregation, exists in two enantiomeric forms in 1:1 ratio. Here, we characterized the anti-platelet effect of S- and R-indobufen using response surface modeling using NONMEM® and predicted the therapeutic doses exerting the maximal efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Noh, Yook-Hwan, Han, Sungpil, Choe, Sangmin, Jung, Jin-Ah, Hwang, Ae-Kyung, Lim, Hyeong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989252/
https://www.ncbi.nlm.nih.gov/pubmed/32055570
http://dx.doi.org/10.12793/tcp.2018.26.4.160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989252/
https://www.ncbi.nlm.nih.gov/pubmed/32055570
http://dx.doi.org/10.12793/tcp.2018.26.4.160

Ejemplares similares